Sirolimus-loaded polyurethane graft for hemodialysis access in sheep

Vascular

Volumn 16, Issue 5, 2008, Pages 269-274

  Schuman, Earl ^a,c   Babu, Jayaraman ^b  

^a Oregon Surgical Consultants   (United States)

^b Thoratec Labs   (United States)

^c NONE   (United States)

Author keywords

Drug eluting graft; Hemodialysis access; Hyperplasia; Intimal hyperplasia; Sirolimus

Indexed keywords

POLYURETHAN; RAPAMYCIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ECHOGRAPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; LIFE TABLE METHOD; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; SHEEP; STATISTICAL SIGNIFICANCE; STENOSIS; VALIDITY; VASCULAR ACCESS DEVICE; VASCULAR PATENCY; ANIMAL; ARTERIOVENOUS SHUNT; BLOOD VESSEL PROSTHESIS; DRUG ADMINISTRATION; DRUG EFFECT; DRUG ELUTING STENT; EVALUATION; GRAFT OCCLUSION; HYPERPLASIA; INTIMA; METHODOLOGY; PATHOLOGY; PILOT STUDY; RENAL REPLACEMENT THERAPY;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD VESSEL PROSTHESIS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; PILOT PROJECTS; RENAL DIALYSIS; SHEEP; SIROLIMUS; TUNICA INTIMA; VASCULAR PATENCY;

EID: 62149095079     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.2310/6670.2008.00032     Document Type: Article

References (28)

1. Rayner HC, Besarab A, Brown WW, et al. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines. Am J Kidney Dis 2004;44(5 Suppl 3):22-6.
2. Gibson KD, Gillen DL, Caps MT, et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 2001;34:694-700.
3. Roy-Chaudry P, Kelly B, Narayana A, et al. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Adv Renal Replace Ther 2004;2:74-84.
4. Schachner T, Zou Y, Oberhuber A, et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 2004;77:1580-5.
5. Gershlick AH, Lotan C, Urban P, et al. The use of sirolimus eluting stents in the treatment of SVG: real world experience from the e-Cypher international registry. Am J Cardiol 2004;94 Suppl 6A:209E.
6. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft with sirolimus eluting stent implantation: immediate and midterm results. Am J Cardiol 2004;94 Suppl 6A:64E.
7. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug eluting stents for the prevention of restenosis. Catheter Cardiovasc Intervent 2002;55: 409-17.
8. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305-7.
9. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
10. Teirstein PS. Living the dream of no restenosis. Circulation 2001; 104:1996-8.
11. Waller JR, Murphy GJ, Bicknell GR, et al. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia. Br J Surg 2002;89:1390-5.
12. Machan L. Drug eluting stents in the infrainguinal circulation. Tech Vasc Interv Radiol 2004;7:28-32.
13. Waller JR, Bicknell GR, Nicholson ML. Sirolimus attenuates the expression of metalloproteinase-2 and -9 and inhibits intimal hyperplasia following balloon angioplasty. Transplant Proc 2002; 34:2881-3.
14. Duda SH, Pusich B, Richter G, et al. Sirolimus eluting stents for the treatment of obstructive superficial femoral artery disease. Circulation 2002;106:1505-9.
15. Farrar DJ, Litwak P, Lawson JH, et al. In vivo evaluation of a new thromboresistance polyurethane for artificial heart blood pump. J Thorac Cardiovasc Surg 1988;95:191-200.
16. Kohler TR, Kirkman TR. Dialysis access failure; a sheep model of rapid stenosis. J Vasc Surg 1999;30:744-51.
17. Roque M, Reis ED, Cordon-Cardo C, et al. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest 2001;81: 895-903.
18. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
19. Waller JR, Brook NR, Bicknell GR, Nicholson ML. Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia. Transplant Int 2004;17:9-14.
20. Walpoth BH, Pavlicek M, Celik B, et al. Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001;19:487-92.
21. Moliterno DJ. Healing Achilles - sirolimus versus paclitaxel. N Engl J Med 2005;353:724-7.
22. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
23. Aoki J, Abizaid AC, Serruys PW, et al. Evaluation of four year coronary artery response after sirolimus eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event free patients. J Am Coll Cardiol 2005;46:1670-6.
24. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus eluting stent implantation: long-term (up to 2 years) clinical, angiographic and intravascular ultrasound follow-up. Circulation 2002;106:1610-3.
25. Ge L, Iakovu I, Cosgrave I, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005;26:1049-51.
26. Weber F, Schneider H, Schwartz C, et al. Sirolimus-eluting stents for percutaneous coronary intervention in acute myocardial infarction: lesson from a case-controlled comparison of bare metal versus drug-eluting stents in thrombus-laden lesions. Z Kardiol 2004;93:938-43.
27. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for treatment of obstructive superficial femoral artery disease. Circulation 2002;106:1505-9.
28. Duda SH, Bosiers M, Lammer J, et al. SIROCCO II study: sirolimus-coated SMART stents for the treatment of obstructive superficial femoral artery disease. Am J Cardiol 2004;94 Suppl 6A:5E.